These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 17941935)

  • 1. Efficacy of low-dose dexamethasone in castration-refractory prostate cancer.
    Venkitaraman R; Thomas K; Huddart RA; Horwich A; Dearnaley DP; Parker CC
    BJU Int; 2008 Feb; 101(4):440-3. PubMed ID: 17941935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
    Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
    BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity of ketoconazole after taxane-based chemotherapy in castration-resistant prostate cancer.
    Nakabayashi M; Oh WK; Jacobus S; Regan MM; Taplin ME; Kantoff PW; Rosenberg JE
    BJU Int; 2010 May; 105(10):1392-6. PubMed ID: 19863532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases.
    Koutsilieris M; Mitsiades CS; Bogdanos J; Dimopoulos T; Karamanolakis D; Milathianakis C; Tsintavis A
    Clin Cancer Res; 2004 Jul; 10(13):4398-405. PubMed ID: 15240528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modular therapy approach in metastatic castration-refractory prostate cancer.
    Walter B; Rogenhofer S; Vogelhuber M; Berand A; Wieland WF; Andreesen R; Reichle A
    World J Urol; 2010 Dec; 28(6):745-50. PubMed ID: 20490506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomised phase 2 trial of dexamethasone versus prednisolone in castration-resistant prostate cancer.
    Venkitaraman R; Lorente D; Murthy V; Thomas K; Parker L; Ahiabor R; Dearnaley D; Huddart R; De Bono J; Parker C
    Eur Urol; 2015 Apr; 67(4):673-9. PubMed ID: 25457497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The postchemotherapy PSA surge syndrome.
    Thuret R; Massard C; Gross-Goupil M; Escudier B; Di Palma M; Bossi A; de Crevoisier R; Chauchereau A; Fizazi K
    Ann Oncol; 2008 Jul; 19(7):1308-1311. PubMed ID: 18356135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multi-centre randomised phase III trial of Dexamethasone vs Dexamethasone and diethylstilbestrol in castration-resistant prostate cancer: immediate vs deferred Diethylstilbestrol.
    Shamash J; Powles T; Sarker SJ; Protheroe A; Mithal N; Mills R; Beard R; Wilson P; Tranter N; O'Brien N; McFaul S; Oliver T
    Br J Cancer; 2011 Feb; 104(4):620-8. PubMed ID: 21285990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate-specific antigen levels and prognosis in patients with hormone-refractory prostate cancer treated with low-dose dexamethasone.
    Morioka M; Kobayashi T; Furukawa Y; Jo Y; Shinkai M; Matsuki T; Yamamoto T; Tanaka H
    Urol Int; 2002; 68(1):10-5. PubMed ID: 11803262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Phase 2 Randomized Controlled Trial of Personalized Peptide Vaccine Immunotherapy with Low-dose Dexamethasone Versus Dexamethasone Alone in Chemotherapy-naive Castration-resistant Prostate Cancer.
    Yoshimura K; Minami T; Nozawa M; Kimura T; Egawa S; Fujimoto H; Yamada A; Itoh K; Uemura H
    Eur Urol; 2016 Jul; 70(1):35-41. PubMed ID: 26782346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer.
    Miyake H; Hara I; Eto H
    BJU Int; 2005 Oct; 96(6):791-5. PubMed ID: 16153202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of estrogens in the secondary hormonal manipulation of hormone refractory prostate cancer.
    Siddiqui K; Abbas F; Biyabani SR; Ather MH; Talati J
    J Pak Med Assoc; 2004 Sep; 54(9):445-7. PubMed ID: 15518364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hormone/antihormone withdrawal and dexamethasone for hormone-refractory prostate cancer.
    Nishiyama T; Terunuma M
    Int J Urol; 1998 Jan; 5(1):44-7. PubMed ID: 9535600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diethylstilbestrol in castration-resistant prostate cancer.
    Wilkins A; Shahidi M; Parker C; Gunapala R; Thomas K; Huddart R; Horwich A; Dearnaley D
    BJU Int; 2012 Dec; 110(11 Pt B):E727-35. PubMed ID: 23110500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting FSH in androgen-independent prostate cancer: abarelix for prostate cancer progressing after orchiectomy.
    Beer TM; Garzotto M; Eilers KM; Lemmon D; Wersinger EM
    Urology; 2004 Feb; 63(2):342-7. PubMed ID: 14972486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of the somatostatin analog octreotide acetate on circulating insulin-like growth factor-1 and related peptides in patients with non-metastatic castration-resistant prostate cancer: results of a phase II study.
    Friedlander TW; Weinberg VK; Small EJ; Sharib J; Harzstark AL; Lin AM; Fong L; Ryan CJ
    Urol Oncol; 2012; 30(4):408-14. PubMed ID: 20884247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metronomic oral cyclophosphamide chemotherapy possibly contributes to stabilization of disease in patients with metastatic castration-resistant prostate cancer: a prospective analysis of consecutive cases.
    Yashi M; Nishihara D; Mizuno T; Yuki H; Masuda A; Kambara T; Betsunoh H; Abe H; Fukabori Y; Muraishi O; Kamai T
    Clin Genitourin Cancer; 2014 Oct; 12(5):e197-203. PubMed ID: 24674784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Corticosteroid-induced inhibition of adrenal androgen production in selected patients with prostate cancer.
    Khandwala HM; Vassilopoulou-Sellin R; Logethetis CJ; Friend KE
    Endocr Pract; 2001; 7(1):11-5. PubMed ID: 11250762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of metronomic oral cyclophosphamide with low dose dexamethasone and celecoxib in metastatic castration-resistant prostate cancer.
    Jeong Y; Lee JL
    Asia Pac J Clin Oncol; 2017 Jun; 13(3):204-211. PubMed ID: 27521286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of dutasteride plus ketoconazole in castration-refractory prostate cancer after progression on ketoconazole alone.
    Sartor O; Nakabayashi M; Taplin ME; Ross RW; Kantoff PW; Balk SP; Oh WK
    Clin Genitourin Cancer; 2009 Oct; 7(3):E90-2. PubMed ID: 19815488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.